SCHEMBL5545522

SCHEMBL5545522

CNC(=O)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2n(CC2CCCO2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.41
ALDH1A1 P00352 9/20 0.41
KDM4E B2RXH2 5/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
RAB9A P51151 2/20 0.40
HSD17B10 Q99714 5/20 0.40
CASP1 P29466 3/20 0.40
CASP7 P55210 3/20 0.40
CYP1A2 P05177 3/20 0.40
CYP2D6 P10635 3/20 0.40
HIF1A Q16665 2/20 0.40
LMNA P02545 2/20 0.40
HTT P42858 1/20 0.40
USP2 O75604 1/20 0.40
HPGD P15428 3/20 0.40
TSHR P16473 3/20 0.40
S1PR4 O95977 1/20 0.40
S1PR1 P21453 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541019 0.90 GAA (0.40) RXFP1ALDH1A1KDM4EGAAKMT2A
SCHEMBL5547423 0.90 TSHR (0.42) RXFP1ALDH1A1KDM4EGAAKMT2A
SCHEMBL5547046 0.88 GSK3B (0.42) ALDH1A1KMT2AHSD17B10HIF1AMEN1
SCHEMBL5545904 0.84 BRD4 (0.42) KMT2AHIF1AMEN1FEN1CNR1
SCHEMBL5541128 0.84 GAA (0.51) RXFP1ALDH1A1KDM4EGAAKMT2A
SCHEMBL5540620 0.83 GAA (0.51) RXFP1ALDH1A1KDM4EGAAKMT2A
SCHEMBL5545807 0.83 GAA (0.50) RXFP1ALDH1A1KDM4EGAAKMT2A
SCHEMBL5545860 0.82 GAA (0.49) RXFP1ALDH1A1KDM4EGAAKMT2A
SCHEMBL5541201 0.81 CNR2 (0.46) POLBCNR1CNR2
SCHEMBL5545426 0.81 L3MBTL1 (0.42) RXFP1ALDH1A1KMT2ASMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 RXFP1 4660/4885ALDH1A1 3812/4885KDM4E 1268/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 RXFP1 4715/4885ALDH1A1 3073/4885KDM4E 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.